docetaxel anhydrous has been researched along with Carcinoma, Ductal, Breast in 177 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.69) | 18.2507 |
| 2000's | 67 (37.85) | 29.6817 |
| 2010's | 102 (57.63) | 24.3611 |
| 2020's | 5 (2.82) | 2.80 |
| Authors | Studies |
|---|---|
| Fujisawa, T; Higaki, K; Ishiguro, H; Kadoya, T; Kaneko, K; Masuda, N; Matsunami, N; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Sato, N; Takahashi, M; Takano, T; Tanaka-Mizuno, S; Toi, M; Yamamoto, Y; Yanagita, Y | 1 |
| Chow, E; De Angelis, C; Jerzak, KJ; Monteiro, M; Rico, V; Shibahara, Y; Slodkowska, E; Tam, S; Zaki, P | 1 |
| Bueno, C; Carolla, RL; Chen, B; Hillman, DW; Jenkins, RB; Johnson, DB; Leon-Ferre, RA; Moreno-Aspitia, A; Northfelt, DW; Perez, AT; Perez, EA; Zon, RT | 1 |
| Akpa, AA; Bathily, M; Berthe, D; Cisse, HL; Dao, S; Dembele, JP; Diabate, K; Diakite, A; Diallo, DA; Diarra, B; Diarra, IM; Fofana, Y; Guindo, I; Konate, M; Kone, AA; Kone, AC; Kone, AS; Kone, J; Minta, D; Ouattara, BZ; Sidibe, A; Sidibe, FM; Sidibe, S; Soumare, MD; Toloba, Y; Toure, BA | 1 |
| Bienkowska, J; Bonato, V; Ching, KA; Cho, SY; Choi, YL; Deng, S; Ding, Y; Fernandez, D; Hwang, S; Kan, Z; Kang, ES; Kim, J; Kim, JY; Kim, SW; Kim, YJ; Lal, S; Lee, JE; Lee, SH; Lee, SK; Nam, JY; Nam, SJ; Park, S; Park, WY; Park, YH; Powell, E; Ram, S; Rejto, PA; Shin, H; Wang, S; Wen, J; Yu, JH | 1 |
| Asmar, L; Blum, JL; Brufsky, AM; Colangelo, LH; Dang, CT; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Gómez, HL; Hopkins, JO; Jacobs, SA; Jeong, JH; Jones, SE; Lyss, AP; Mamounas, EP; O'Shaughnessy, JA; Paul, D; Robert, NJ; Swain, SM; Vukelja, SJ; Wolmark, N; Yothers, G | 1 |
| Lamichhane, S; Shah, RK | 1 |
| Boggiani, D; Musolino, A; Palli, D; Pellegrino, B; Tommasi, C | 1 |
| Ameye, L; Anderson, M; Campbell, I; Crown, J; de Azambuja, E; Di Leo, A; Francis, PA; Gelber, RD; Gnant, M; Goldhirsch, A; Gutiérez, J; Habib, JG; Joseph, DJ; Lluch, A; Nordenskjöld, B; Paesmans, M; Piccart-Gebhart, M; Zeidan, YH | 1 |
| Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF | 1 |
| Banke, A; Cold, S; Dahl, JS; Ewertz, M; Fosbøl, EL; Gislason, GH; Jensen, MB; Møller, JE; Poulsen, MK; Schou, M; Videbæk, L | 1 |
| Hahn, SY; Han, BK; Im, YH; Kim, RB; Ko, ES; Ko, EY; Lee, JE; Lee, SK; Nam, SJ; Park, YH; Shin, JH | 1 |
| Henry-Tillman, RS; Hutchins, LF; Klimberg, VS; Korourian, S; Makhoul, I; Siegel, ER; Westbrook, KC | 1 |
| Andre, F; Chan, A; Chan, S; Gianni, L; Greil, R; Lichinitser, M; Lipatov, O; Mansutti, M; Mariani, P; Moore, N; Pallaud, C; Pivot, X; Prot, S; Romieu, GH; Semiglazov, V; Serrano, SV; Wardley, A | 1 |
| Ballardini, P; Borghi, A; Corazza, M; Minghetti, S; Virgili, A | 1 |
| Chen, J; Huan, Y; Li, D; Wang, J; Wang, L; Wang, T; Yao, Q; Yu, M; Zhang, J; Zhou, X | 1 |
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Dillon, PM; Greer, KE; Marchetti, MA; Noland, MM | 1 |
| Delaloge, S; Dunant, A; Garbay, JR; Kane, A; Leymarie, N; Mazouni, C; Naveau, A; Rimareix, F; Sarfati, B | 1 |
| Bauerfeind, I; Blohmer, JU; Costa, SD; Denkert, C; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Böttcher, J; Engelken, FJ; Fallenberg, EM; Hamm, B; Maurer, MH; Pfeil, A; Renz, DM; Streitparth, F; Zahm, DM | 1 |
| Champagne, C; Gaillot-Petit, N; Guilbert, P; Lamberth, F; Looten-Vieren, L; Nguyen, TD | 1 |
| Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC | 1 |
| Zhou, X | 1 |
| Habiro, T; Hatate, K; Hayashi, K; Oshida, S; Sengoku, N | 1 |
| Dhakal, I; Griffin, RJ; Hutchins, LF; Jamshidi-Parsian, A; Kadlubar, S; Klimberg, S; Lee, J; Makhoul, I; Raj, V; Siegel, E | 1 |
| Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH | 1 |
| Chan, MS; Chen, SF; Chow, LW; Felizola, SJ; Ishida, T; Nemoto, N; Ohuchi, N; Sasano, H; Tamaki, K; Wang, L | 1 |
| Belli, P; Bufi, E; D' Agostino, GR; De Santis, MC; Diletto, B; Franceschini, G; Mulé, A; Nardone, L; Sapino, A; Terribile, D; Valentini, V | 1 |
| Li, J; Li, X; Liu, H; Liu, M; Wang, J; Xu, J; Yang, H; Zhang, Y | 1 |
| Bonetti, F; Bria, E; Brunelli, M; Caliolo, C; Carbognin, L; Furlanetto, J; Manfrin, E; Massari, F; Nortilli, R; Pedron, S; Pellini, F; Pollini, GP; Scarpa, A; Sperduti, I; Tortora, G | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Ham, HS; Han, W; Im, SA; Jang, IJ; Keam, B; Kim, HJ; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Noh, DY; Oh, DY; Park, IA | 1 |
| Arakawa, A; Harada-Shoji, N; Himuro, T; Hino, O; Horimoto, Y; Igari, F; Mamat, O; Saito, M; Sonoue, H; Tanabe, M; Tokuda, E; Yoshida, Y | 1 |
| Amarillo, I; Fisher, SI; Rashidi, A | 1 |
| Arnould, L; Bachelot, T; Berriolo-Riedinger, A; Bougnoux, P; Coeffic, D; Coudert, B; Coudert, M; Dupré, PF; Ferrero, JM; Gabelle, P; Giard, S; Hernandez, J; Kerbrat, P; Kerrou, K; Mouret-Reynier, MA; Paintaud, G; Petit, T; Pierga, JY; Prevost, JB; Thibault, G | 1 |
| Fu, L; Gu, F; Guo, X; Li, H; Li, S; Li, X; Liu, F; Zhai, L; Zhang, X | 1 |
| Barni, S; Botti, G; Colantuoni, G; D'Aiuto, M; Daniele, B; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Di Maio, M; Di Rella, F; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Iodice, G; Labonia, V; Landi, G; Lauria, R; Montanino, A; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Aksoy, S; Altundag, K; Berk, V; Karaca, H; Ozdemir, N; Ozkan, M; Ozturk, B; Sendur, MA; Yazici, O; Yazilitas, D; Zengin, N | 1 |
| Boukovinas, I; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Malamos, N; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N | 1 |
| Bachelot, T; Boher, JM; Delva, R; Dohollou, N; Eymard, JC; Fabbro, M; Ferrero, JM; Gonçalves, A; Leduc, B; Lemonnier, J; Lerebours, F; Linassier, C; Lotz, JP; Martin, AL; Mouret-Reynier, MA; Pierga, JY; Roché, H; Viens, P | 1 |
| Aydiner, A; Cabioglu, N; Deniz, M; Erturk, K; Karanlik, H; Kilic, B; Onder, S; Ozgur, I; Sen, F; Yavuz, E | 1 |
| Cai, SQ; Chen, XB; Dou, TT; Man, XY; Min, M; Yang, JQ; Zheng, M | 1 |
| Choi, DH; Huh, SJ; Keum, KC; Kim, KH; Kim, YB; Noh, JM; Park, W; Suh, CO | 1 |
| Abrial, C; Bahadoor, MR; Benmammar, KE; Bignon, YJ; Cayre, A; Chalabi, N; Chollet, P; Dauplat, MM; Durando, X; Jacquin, JP; Kullab, S; Kwiatkowski, F; Mouret-Reynier, MA; Nabholtz, JM; Penault-Llorca, F; Radosevic-Robin, N; Servent, V; Van Praagh, I | 1 |
| Darb-Esfahani, S; Denkert, C; Eidtmann, H; Fasching, PA; Furlanetto, J; Hartmann, A; Huober, J; Jackisch, C; Klimowicz, A; Lederer, B; Loibl, S; Mehta, K; Pfitzner, B; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Chen, K; Chen, Y; Gong, C; Nie, Y; Qu, S; Song, E; Su, F; Xiao, X | 1 |
| Bernardo, PS; Buarque, CD; Costa, PR; Delbue, D; Lam, EW; Lemos, LG; Maia, RC; Nestal de Moraes, G; Vasconcelos, Fda C | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Hamaoka, A; Konishi, E; Matsuda, T; Taguchi, T | 1 |
| Kang, Y; Li, J; Ma, Y; Ren, W; Zang, L; Zhang, S | 1 |
| Cesana, P; Conen, K; Gotta, V; Hammann, F; Medinger, M; Rochlitz, C; Taegtmeyer, AB | 1 |
| Aguirresarobe-Gil de San Vicente, M; Aresti, S; Cabriada-Nuno, JL; de Miguel, E; Hidalgo-Blanco, A | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E | 1 |
| Hino, M; Homma, K; Sano, M; Sato, N | 1 |
| Fujii, K; Fukutomi, T; Hara, K; Mouri, Y; Nakano, S; Nakaoka, T; Yamada, S; Yorozuya, K; Yoshida, M | 1 |
| Guo, QS; Liu, ZF; Song, SP; Wang, MY; Wu, N; Yang, XG; Zhang, XQ | 1 |
| Jiang, WQ; Lin, XB; Liu, DG; Teng, XY; Zhong, JT; Zhou, NN | 1 |
| Duarte, M; García-Sancho, L; Gil-López, JM; Trébol, J | 1 |
| Boidot, R; Coudert, B; Fumoleau, P; Lizard-Nacol, S; Soubeyrand, MS; Vegran, F | 1 |
| Alfonso, PG; Cañón, EP; Carrión, JB; Manga, GP; Pereira, RQ; Peron, YI; Plaza, MI; Shahi, PK; Ureña, MM; Val, RG | 1 |
| García-Donas Jiménez, J; Jara Sánchez, C; Olier Gárate, C; Peñalver Párraga, J | 1 |
| Bergh, J; Castany, R; Liljegren, A | 1 |
| Abe, M; Doiguchi, M; Hasuo, T; Miyamoto, Y; Sakamoto, F; Tanigawa, T | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Siau, K; Varughese, M | 1 |
| Brites, MM; Figueiredo, A; Frutuoso, C; Saleiro, S; Santiago, F | 1 |
| Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H | 1 |
| Antonini, N; Linn, SC; Loo, CE; Oldenburg, HS; Rodenhuis, S; Russell, NS; Rutgers, EJ; Straver, ME; Vrancken Peeters, MT; Wesseling, J | 1 |
| Fox, J; Ganju, V; Hart, S; Hofman, M; Midolo, P; Schneider-Kolsky, ME; Stuckey, J | 1 |
| Bauknecht, T; Bottini, A; Kennedy, L; Manikhas, AG; Mansouri, K; Marmé, F; Ruiz, A; Schneeweiss, A; Sinn, HP; Wolf, M | 1 |
| Allmaier, G; Bachleitner-Hofmann, T; Bartsch, R; Baumann, S; Bergmann, M; Burghuber, C; Gnant, M; Graf, A; Greil, R; Marchetti-Deschmann, M; Michlmayr, A; Oehler, R; Pluschnig, U; Rech-Weichselbraun, I; Steger, G | 1 |
| Baumann, I; Darb-Esfahani, S; Denkert, C; Grasshoff, ST; Heinrich, G; Hoffmann, G; Kronenwett, R; Loibl, S; Müller, BM; Noske, A; Roller, M; Steffen, J; Ulmer, HU; von Minckwitz, G; von Toerne, C; Wirtz, R | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Ohkubo, T; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Hillemanns, P; Kramer, F; Park-Simon, TW; Rinnau, F; Schippert, C | 1 |
| Kajiura, Y; Yagata, H; Yamauchi, H | 1 |
| Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl | 1 |
| Halim, A; Wahba, H | 1 |
| Bando, H; Iwata, H; Kashiwaba, M; Mizuno, T; Murakami, S; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Yamamoto, Y | 1 |
| Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L | 1 |
| Bluemke, DA; Gabrielson, E; Jacobs, MA; Jeter, S; Ouwerkerk, R; Stearns, V; Wahl, R; Warzecha, H; Wolff, AC | 1 |
| Caldés, T; Casado, A; Cheang, MC; de la Torre, J; Diaz-Rubio, E; Furio, V; García-Saenz, JA; He, X; López García-Asenjo, JA; Lopez-Tarruella, S; Martin, M; Oliva, B; Perou, CM; Puente, J; Román, JM; Romero, A; Vidart, JA | 1 |
| Amoroso, D; Camerini, A; Cavazzana, A; De Luca, F; Donati, S; Martini, L; Puccetti, C; Siclari, O; Tartarelli, G; Valsuani, C; Viacava, P | 1 |
| Bair, AH; Bycott, P; Chan, S; Joy, AA; Kim, S; Liau, KF; Lluch, A; Rosbrook, B; Rugo, HS; Soulieres, D; Stopeck, AT; Verma, S | 1 |
| Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Alles, JU; Ataseven, B; Darb-Esfahani, S; Denkert, C; du Bois, A; Fissler-Eckhoff, A; Gerber, B; Kulmer, U; Loibl, S; Mehta, K; Müller, BM; Roller, M; Schwabe, M; von Minckwitz, G | 1 |
| Almanza, C; Alvarez, E; Antolín, S; Calvo, L; de Paz, L; García-Mata, J; García-Palomo, A; González, A; Mel, R; Ramos, M | 1 |
| Crane, K | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Bang, YJ; Cho, N; Chung, JK; Han, SW; Han, W; Im, SA; Kang, KW; Keam, B; Kim, JH; Kim, TY; Koh, Y; Moon, WK; Noh, DY; Oh, DY; Park, IA | 1 |
| Mahmood, A; Rahman, A | 1 |
| Bergh, J; Bischoff, J; Bondarenko, IM; Chan, A; Cortes, J; Delaloge, S; Giorgetti, C; Greil, R; Huang, X; Kern, KA; Lichinitser, MR; Liljegren, A; Lortholary, A; Makhson, AN; Voytko, NL | 1 |
| Arai, T; Kamigaki, S; Matsuura, M; Oshiro, C | 1 |
| Awada, A; Bergh, J; Cardoso, F; Gianni, L; Giorgetti, C; Huang, X; Kern, KA; Liljegren, A; Mariani, G; Verkh, L; Viganò, L | 1 |
| Guli, KZ; Guo, L; Hu, X; Li, X; Li, Y; Liu, W; Ma, Y; Wen, SJ; Yang, SE; Zhao, B | 1 |
| Anderson, J; Barham, T; Chan, A; Hastrich, DJ; Ingram, D; Joseph, D; Latham, B; Redfern, A; Thomson, J; VAN DER Schaaf, A; Willsher, PC | 1 |
| Loibl, S; Massey Skatulla, L; Müller, T; Schauf, B | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ | 1 |
| Chen, H; Chen, WJ; Sun, HY; Wu, LL; Yuan, SF; Zhang, W; Zheng, WE; Zhu, LJ | 1 |
| Bonnefoi, H; Brouste, V; Debled, M; Donamaria, C; Durand, M; MacGrogan, G; Madranges, N; Mauriac, L; Toulmonde, M | 1 |
| Bleuse, JP; Chapelle, A; Jacot, W; Lamy, PJ; Pouderoux, S; Romieu, G; Thezenas, S | 1 |
| Baselga, J; Bombonati, A; Rafferty, EA; Smith, BL | 1 |
| Belli, P; Bonatesta, A; Bonomo, L; Bufi, E; Costantini, M; De Santis, MC; Di Matteo, M; Mulé, A; Nardone, L; Rinaldi, P; Terribile, D | 1 |
| Heys, SD; McKenzie, EJ; Miller, ID; Rees, AJ; Sellar, G; Stewart, KN; Wong, SY | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P | 1 |
| Abahssain, H; Aitelhaj, M; Bensouda, Y; Errihani, H; Khannoussi, B; Khoyaali, S; Mrabti, H; Naciri, S; Rais, F; Rais, G; Raissouni, S | 1 |
| Cao, X; Xue, J; Zhao, B | 1 |
| Caldés, T; de la Hoya, M; Díaz-Rubio, E; Fuentes-Ferrer, M; Furió, V; García-Sáenz, JA; López Garcia-Asenjo, JA; Martín, M; Moreno, A; Román, JM; Romero, A | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Blot, E; Bonneterre, J; Desauw, C; Fournier, C; Hornez, L; Kramar, A; Peyrat, JP; Révillion, F | 1 |
| Fersching, DM; Holdenrieder, S; Lehner, J; Nagel, D; Stötzer, OJ | 1 |
| Che, L; Di, L; Jia, J; Jiang, H; Liang, X; Lyerly, HK; Ren, J; Song, G; Wan, F; Wang, X; Yan, Y; Yu, J; Zhang, J; Zhou, X; Zhu, Y | 1 |
| Antón, A; Aranda, E; Dalmau, E; de la Haba-Rodríguez, J; Fernández, M; Jaén, A; Llombart, A; Lomas, M; Morales, S; Porras, I; Sánchez, A; Sánchez-Rovira, P; Seguí, MA | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T | 1 |
| Aida, Y; Chishima, Y; Kitajima, A; Noro, M; Okamoto, H; Satou, Y; Takano, S | 1 |
| Abali, H; Celik, I | 1 |
| Fukushima, M; Ono, Y; Sawada, M | 1 |
| Arizcun, A; Cruz, JJ; del Barco, E; Diz, P; Fonseca, E; García-Palomo, A; Gómez-Bernal, A; López, Y; Martín, G; Pujol, E; Rodríguez, C; Sánchez, P | 1 |
| Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T | 1 |
| Mio, H | 1 |
| Bachelot, T; Bendahmane, B; Combe, M; De Ybarlucea, LR; Dieras, V; Fumoleau, P; Ganem, G; Lotz, V; Misset, JL; Tubiana-Hulin, M; Vannetzel, JM | 1 |
| Fujii, H; Ichihara, F; Inoue, S; Kono, K; Kunitomo, K; Matsumoto, Y; Ooi, A | 1 |
| Julka, PK; Mukhopadhyay, P; Rath, GK; Sharma, DN | 1 |
| Hashimoto, K; Higami, T; Itakura, M; Koike, M; Nio, Y; Yano, S | 1 |
| Blohmer, JU; Dieing, A; Eggemann, H; Elling, D; Heilmann, V; Krocker, J; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Sezer, O | 1 |
| Arizcun, A; Cruz, JJ; Fonseca, E; Gómez-Bernal, A; Martín, G; Martín, T; Olaverri, A; Rodríguez, CA; Sánchez, P | 1 |
| Griffith, KA; Kleer, CG; Pu, RT; Schott, AF; Sturtz, DE | 1 |
| Alexopoulos, A; Apostolikas, N; Ardavanis, A; Karamouzis, MV; Papadopoulou, A; Rigatos, G | 1 |
| Cajozzo, M; Comella, G; Condemi, G; Danova, M; De Cataldis, G; Farris, A; Ferraù, F; Filippelli, G; Iannitto, E; Leonardi, V; Macaluso, MC; Mangiameli, A; Massidda, B; Misino, A; Palmeri, L; Palmeri, S; Spada, S; Vaglica, M | 1 |
| Hitzl, W; Peintinger, F; Prokop, E; Reitsamer, R | 1 |
| Borgia, F; Guarneri, C; Guarneri, F; Vaccaro, M | 1 |
| Erkisi, M; Kara, IO; Sahin, B | 1 |
| Kato, K; Kim, SJ; Miyoshi, Y; Nakamura, H; Noguchi, S; Taguchi, T; Tamaki, Y; Yodoi, J | 1 |
| Asproudis, I; Gorezis, S; Peschos, D; Psilas, K; Stefaniotou, M | 1 |
| Burton, GV; Lewis, D; Potluri, V | 1 |
| Kato, K; Noguchi, S; Ooe, A | 1 |
| Blohmer, JU; Dan Costa, S; du Bois, A; Eidtmann, H; Gerber, B; Hilfrich, J; Jackisch, C; Kaufmann, M; Loibl, S; Petrich, S; Raab, G; von Minckwitz, G | 1 |
| Ahr, A; Gätje, R; Holtrich, U; Karn, T; Kaufmann, M; Kissler, S; Kourtis, K; Loibl, S; Munnes, M; Rody, A; Ruckhäberle, E; Solbach, C; von Minckwitz, G | 1 |
| Angellier, E; Berdah, JF; Buyse, M; Fabbro, M; Greget, S; Herait, P; Jehl, V; Laplaige, P; Piedbois, P; Priou, F; Serin, D; Teissier, E; Valenza, B | 1 |
| Burla, ML; Dauphine, CE; Gonzalez, KD; Isaac, NM; Kaufmann, P; Rosing, D; Vargas, HI; Vargas, MP | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Haid, A; Hussian, D; Jakesz, R; Lang, A; Pluschnig, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Blanc-Fournier, C; Chasle, J; Guedin, P; Lacroix, J | 1 |
| Hata, Y; Taguchi, K; Takahashi, H; Takahashi, M; Tamura, M; Todo, S; Watanabe, K | 1 |
| Suzuki, M | 1 |
| Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S | 1 |
| Jiang, DQ; Li, S; Long, F; Xu, H; Zhang, B; Zhang, Q; Zhao, L | 1 |
| Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM | 1 |
| Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S | 1 |
| Galid, A; Gnant, M; Greil, R; Haid, A; Jakesz, R; Klug, E; Kubista, E; Kwasny, W; Lang, A; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Singer, CF; Steger, GG; Tausch, C; Wenzel, C | 1 |
| Sekar, R; Stone, PR | 1 |
| Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G | 1 |
| Fu, JM; Li, H; Xie, JS; Zhou, J | 1 |
| Arima, N; Iwase, H; Kai, K; Miyayama, H; Nishimura, R; Yamamoto, Y | 1 |
| Di Nunno, L; Herrington, JD; Rinehart, JJ | 1 |
| Kurihara, M; Matsuno, S; Ohashi, Y; Okada, S; Sakata, Y; Sasaki, Y; Taguchi, T | 1 |
| Hada, M; Hagiwara, J; Kamiya, K; Koshizuka, K; Muto, S; Nakagomi, H; Tada, Y; Takano, K | 1 |
| Doi, K; Inoue, K; Ishihara, A; Kimura, Y; Kudo, S; Ochiai, T; Ohchi, T; Sakae, T; Sakamoto, T; Takahashi, M | 1 |
| Barbier, P; Bissery, MC; David, S; Fellous, A; Gounon, P; Vantard, M; Veitia, R | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA; Tsavaris, N | 1 |
| Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Giesel, BU; Kutz, GG; Thiel, HJ | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Akaike, H; Ashizawa, I; Chiba, S; Imamura, K; Mitui, T; Miyauchi, Y; Muto, S; Nakagomi, H; Nakazawa, M; Okuda, J; Takahashi, M | 1 |
| Ezumi, K; Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masuda, N; Masutani, S; Miya, A; Satomi, T; Shimizu, J; Tatsuta, M | 1 |
| Oka, M; Saito, K; Takano, N; Tangoku, A | 1 |
| Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K | 1 |
| Ishihama, H | 1 |
| Fleming, D; Hahl, M; Morkas, M | 1 |
| Caruso, A; De Carolis, S; De Santis, M; Ferrazani, S; Lucchese, A | 1 |
| Haegele, P; Lehmann, S; Moyses, B; Petit, T; Rodier, JF; Schraub, S; Velten, M | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
10 review(s) available for docetaxel anhydrous and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Carcinoma, Ductal, Breast; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Dose Fractionation, Radiation; Female; Fibrocystic Breast Disease; Humans; Mastectomy; Sentinel Lymph Node Biopsy; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
[Gastrointestinal symptoms revealing COVID-19 in Malian breast cancer patient undergoing chemotherapy].
Topics: Adult; Antineoplastic Agents, Phytogenic; Betacoronavirus; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Coronavirus Infections; COVID-19; Diarrhea; Docetaxel; Fatal Outcome; Female; HIV Infections; Humans; Liver Neoplasms; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spinal Neoplasms; Tomography, X-Ray Computed; Vomiting; Zoledronic Acid | 2020 |
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.
Topics: Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cross Reactions; Docetaxel; Drug Hypersensitivity; Female; Humans; Paclitaxel; Taxoids | 2017 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Receptors, Estrogen; Taxoids | 2011 |
Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cesarean Section; Cyclophosphamide; Docetaxel; Female; HELLP Syndrome; Humans; Infant, Newborn; Male; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Neoplastic; Taxoids | 2012 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug?
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Contraindications; Docetaxel; Female; Humans; Middle Aged; Radiation-Sensitizing Agents; Radiodermatitis; Taxoids | 2005 |
Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Taxoids | 2006 |
Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Choroid Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Meningeal Neoplasms; Methotrexate; Mitoxantrone; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Recall dermatitis caused by re-exposure to docetaxel following irradiation of the brain. Case report and review of the literature].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Taxoids | 2001 |
58 trial(s) available for docetaxel anhydrous and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Young Adult | 2020 |
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2020 |
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2017 |
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Postoperative Care; Young Adult | 2018 |
Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Black or African American; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Female; Humans; Lymph Nodes; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; White People | 2015 |
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Hypertension; Inflammatory Breast Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Taxoids; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Endostatins; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Taxoids; Young Adult | 2013 |
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Proportional Hazards Models; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Topics: Angiopoietin-1; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fibroblast Growth Factor 2; Humans; Interleukin-1alpha; Matrix Metalloproteinase 9; Neoadjuvant Therapy; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Prospective Studies; Proto-Oncogene Proteins c-sis; Receptor, ErbB-2; Receptor, TIE-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy, Adjuvant; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prospective Studies; Taxoids; Treatment Outcome | 2014 |
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER):
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2014 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2015 |
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Time Factors; Trastuzumab; Young Adult | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2015 |
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cetuximab; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Taxoids; Triple Negative Breast Neoplasms | 2016 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Prevalence; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Young Adult | 2017 |
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome | 2009 |
Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Glutamates; Guanine; Humans; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2011 |
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Complement System Proteins; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Plasma; Predictive Value of Tests; Taxoids; Validation Studies as Topic | 2010 |
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Neoadjuvant Therapy; Prognosis; Prospective Studies; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa | 2011 |
Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Health Status; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; DNA Mutational Analysis; Docetaxel; Female; Fluorouracil; Genomics; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2012 |
Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Radiography; Radiopharmaceuticals; Sodium Isotopes; Taxoids; Treatment Outcome | 2011 |
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Genes, Neoplasm; Humans; Middle Aged; Multivariate Analysis; Taxoids; Treatment Outcome | 2011 |
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypertension; Imidazoles; Indazoles; Middle Aged; Mucositis; Neoplasm Proteins; Neutropenia; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Taxoids; Thrombophilia | 2011 |
A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2011 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Humans; Indoles; International Agencies; Middle Aged; Prospective Studies; Pyrroles; Receptor, ErbB-2; Sunitinib; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Treatment Outcome | 2012 |
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Premenopause; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vomiting | 2012 |
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of su
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Thiotepa | 2013 |
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Taxoids | 2013 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Docetaxel; Female; Humans; India; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Necrosis; Neoadjuvant Therapy; Neoplasm Invasiveness; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Remission Induction; Taxoids; Treatment Outcome | 2005 |
Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line; Chaperonin Containing TCP-1; Chaperonins; Chemotherapy, Adjuvant; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; GTP-Binding Proteins; GTPase-Activating Proteins; Humans; Molecular Chaperones; Neoplasm Proteins; Neoplasm Recurrence, Local; R-SNARE Proteins; RGS Proteins; RNA, Small Interfering; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids | 2006 |
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Genes, erbB-2; Humans; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; tau Proteins; Taxoids | 2007 |
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 rando
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Taxoids | 2007 |
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Taxoids | 2007 |
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Thionucleotides | 2008 |
Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids | 1999 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
110 other study(ies) available for docetaxel anhydrous and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Topics: Anthracyclines; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Ductal, Breast; CD8-Positive T-Lymphocytes; Cell Cycle Proteins; Cyclophosphamide; Disease-Free Survival; Docetaxel; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Interferon Regulatory Factors; Longitudinal Studies; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neoplasm, Residual; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Tumor Microenvironment | 2020 |
Ocular metastasis from breast carcinoma simulating anterior scleritis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Doxorubicin; Eye Neoplasms; Eye Pain; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Scleritis; Taxoids; Tomography, X-Ray Computed | 2017 |
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2019 |
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiotoxicity; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Denmark; Docetaxel; Epirubicin; Female; Heart Failure; Humans; Incidence; Longitudinal Studies; Mastectomy, Segmental; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Risk; Stroke Volume; Trastuzumab | 2019 |
Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; False Negative Reactions; False Positive Reactions; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Statistics, Nonparametric; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Young Adult | 2013 |
Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Secondary Prevention; Taxoids | 2014 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Taxane associated subacute cutaneous lupus erythematosus.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Docetaxel; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Taxoids | 2013 |
The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Esthetics; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Reoperation; Retrospective Studies; Taxoids; Tumor Burden | 2013 |
Response to neoadjuvant treatment of invasive ductal breast carcinomas including outcome evaluation: MRI analysis by an automatic CAD system in comparison to visual evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cohort Studies; Cyclophosphamide; Diagnosis, Computer-Assisted; Docetaxel; Doxorubicin; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Mammography; Mastectomy; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2014 |
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Funnel Chest; Hodgkin Disease; Humans; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Obesity; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids | 2014 |
CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; CD24 Antigen; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Taxoids | 2014 |
[A case of acute appendicitis which occurred during chemotherapy for breast cancer].
Topics: Acute Disease; Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Mastectomy, Segmental; Sentinel Lymph Node Biopsy; Taxoids | 2013 |
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Humans; Incidence; Induction Chemotherapy; Menstruation; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Retrospective Studies; Tamoxifen; Taxoids; Young Adult | 2014 |
Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Forkhead Transcription Factors; Humans; Immunohistochemistry; Immunophenotyping; Lymphocyte Subsets; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Stromal Cells; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Tumor Microenvironment | 2014 |
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Epirubicin; ErbB Receptors; Female; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2014 |
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuz
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Female; Gene Amplification; HSP90 Heat-Shock Proteins; Humans; Ki-67 Antigen; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Female; Gene Frequency; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Taxoids | 2015 |
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Gene Knockdown Techniques; Hepatocyte Nuclear Factor 3-alpha; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2015 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Genes, BRCA2; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Taxoids | 2015 |
The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoadjuvant Therapy; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Retrospective Studies; Taxoids; Trastuzumab | 2015 |
Docetaxel-induced scleroderma: a case report and its role in the production of extracellular matrix.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cells, Cultured; Chemotherapy, Adjuvant; Docetaxel; Extracellular Matrix; Extracellular Matrix Proteins; Female; Fibroblasts; Fibrosis; Humans; Middle Aged; Scleroderma, Diffuse; Skin | 2017 |
Prognostic significance of nodal involvement region in clinical stage IIIc breast cancer patients who received primary systemic treatment, surgery, and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clavicle; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mammary Glands, Human; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Rate; Taxoids | 2015 |
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Cyclophosphamide; DNA Mutational Analysis; Docetaxel; Epirubicin; Gene Expression; Humans; Middle Aged; Mutation; Phosphoproteins; PTEN Phosphohydrolase; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Multivariate Analysis; Neoadjuvant Therapy; Neutrophils; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; G2 Phase; Humans; MCF-7 Cells; Phenotype; Pterocarpans; Taxoids | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
[A Case of Luminal-HER2 Advanced Breast Cancer with Liver Metastasis Showed Pathological Complete Response to the Therapy with Pertuzumab plus Trastuzumab plus Docetaxel].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Phenobarbital; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Elasticity Imaging Techniques; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Ultrasonography, Mammary | 2016 |
Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Drug Interactions; Female; Humans; Paclitaxel; Taxoids; Time Factors; Trastuzumab | 2017 |
Pseudocirrhosis in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Doxorubicin; Fatal Outcome; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Mastectomy; Taxoids; Trastuzumab | 2018 |
Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Axilla; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; False Negative Reactions; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Sentinel Lymph Node Biopsy; Taxoids | 2008 |
A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving long-term treatment with bisphosphonates.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Docetaxel; Female; Humans; Jaw Diseases; Osteonecrosis; Spinal Neoplasms; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2009 |
[Low dose-intensity docetaxel monotherapy for patients with anthracycline-resistant metastatic breast cancer in poor physical status].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2008 |
[Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Topics: Adult; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Exanthema; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neutropenia; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab | 2008 |
[Acute abdomen in a chemotherapy treated breast cancer patient].
Topics: Abdomen, Acute; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Taxoids | 2009 |
Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Taxoids; Thrombocytopenia; Trastuzumab | 2009 |
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Indoles; Liver Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2009 |
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Inflammation; Middle Aged; Oxonic Acid; Skin Neoplasms; Taxoids; Tegafur; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids; Thrombotic Microangiopathies; Trastuzumab; Treatment Outcome | 2010 |
A remarkable case of cutaneous metastatic breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Humans; Mammaplasty; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Nitriles; Radiography; Skin Neoplasms; Taxoids; Triazoles | 2009 |
[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids | 2009 |
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Lymph Node Excision; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Tamoxifen; Taxoids; Tegafur; Trastuzumab; Uracil | 2010 |
The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction After Previous Drug Extravasation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Docetaxel; Drug Eruptions; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Neoplasm Metastasis; Recurrence; Taxoids | 2011 |
Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2011 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, erbB-2; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Androgen; Taxoids | 2011 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sentinel Lymph Node Biopsy; Taxoids; Tomography, X-Ray Computed | 2013 |
Cutis verticis gyrata secondary to infiltrating ductal carcinoma breast.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Hypertrophy; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Scalp Dermatoses; Severity of Illness Index; Skin; Taxoids | 2012 |
[A case of breast cancer with chronic renal failure successfully treated with TC therapy as adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Creatinine; Cyclophosphamide; Docetaxel; Female; Humans; Kidney Failure, Chronic; Middle Aged; Neoplasm Staging; Sentinel Lymph Node Biopsy; Taxoids | 2012 |
[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Receptor, ErbB-2; Remission Induction; RNA, Messenger; Survivin; Taxoids | 2011 |
Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Preoperative Care; Quality of Life; Taxoids; Treatment Outcome | 2012 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vinblastine; Vinorelbine | 2012 |
Expression of β-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Survivin; Taxoids; Tubulin | 2012 |
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.
Topics: Acid Phosphatase; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Breast Neoplasms; Calcium; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Collagen; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Isoenzymes; Middle Aged; Neoadjuvant Therapy; Osteoprotegerin; Peptide Fragments; Prevalence; RANK Ligand; Retrospective Studies; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Vitamin D; Vitamin D Deficiency | 2012 |
Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mastectomy; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Protocols; Combined Modality Therapy; Diffusion Magnetic Resonance Imaging; Docetaxel; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Taxoids | 2012 |
Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer.
Topics: Adult; Aged; Anthracyclines; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials as Topic; Dendritic Cells; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Macrophages; Middle Aged; Multivariate Analysis; T-Lymphocytes; Taxoids; Treatment Outcome; Young Adult | 2012 |
Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Medullary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Mastectomy; Middle Aged; Morocco; Neoplasm Grading; Neoplasm Staging; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Contrast Media; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Ultrasonography, Doppler, Color; Ultrasonography, Mammary | 2012 |
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Proportional Hazards Models; Taxoids; Treatment Outcome; Tumor Burden | 2013 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Protein Array Analysis; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Taxoids | 2013 |
Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; DNA; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2013 |
Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Squamous Cell; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
[Patient with bone metastasis of breast cancer who were improved by weekly DXR/TXT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Paclitaxel; Taxoids | 2002 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Central Nervous System Neoplasms; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2002 |
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids | 2003 |
[A case of postoperative recurrent breast cancer with multiple lung metastases that completely responded to combination therapy of docetaxel (TXT) and medroxyprogesterone acetate (MPA)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Taxoids | 2003 |
A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Fatal Outcome; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Liver Neoplasms; Receptor, ErbB-2; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2004 |
[A case of liver metastases of breast cancer successfully treated by combination chemotherapy using hepatic arterial infusion of docetaxel and systemic administration of trastuzumab].
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Mastectomy, Segmental; Taxoids; Tegafur; Trastuzumab; Uracil | 2004 |
Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Fatal Outcome; Female; Fingers; Humans; Liposomes; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Skin Neoplasms; Taxoids; Toes | 2005 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Erythema; Fatal Outcome; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Paresthesia; Taxoids; Vitamin E | 2006 |
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.
Topics: Antineoplastic Agents, Phytogenic; BRCA1 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Taxoids; Thioredoxins; Tumor Suppressor Protein p53 | 2005 |
Choroidal metastasis from breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Choroid Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2006 |
Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Taxoids; Treatment Outcome | 2006 |
[Breast carcinoma and bone chondrosarcoma: a new syndrome?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chondrosarcoma; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Mammography; Middle Aged; Phenotype; Radiography, Thoracic; Radiotherapy Dosage; Ribs; Syndrome; Taxoids; Tomography, X-Ray Computed | 2006 |
[Efficacy and toxicity of combination treatment with epirubicin (EPI) plus docetaxel (DOC) in advanced breast cancer].
Topics: Adult; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Taxoids | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
[A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Inflammation; Mammography; Middle Aged; Remission Induction; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2007 |
[Assessment of neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Logistic Models; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2006 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Trastuzumab use for metastatic breast cancer in pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Infant, Newborn; Lung Neoplasms; Neoplasm Staging; Oligohydramnios; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Taxoids; Trastuzumab | 2007 |
[Effect of neoadjuvant chemotherapy on ERCC1 gene expression in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2008 |
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2009 |
Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arachnoid; Blood-Brain Barrier; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Meningeal Neoplasms; Paclitaxel; Taxoids | 1998 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
[A trial for neoadjuvant chemotherapy of transarterial infusion of docetaxel in locally advanced breast cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Blotting, Western; Brain; Carcinoma, Ductal, Breast; Cathepsin D; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Immunohistochemistry; Kinetics; Mice; Mice, Inbred C57BL; Microscopy, Electron; Microtubule-Associated Proteins; Microtubules; Molecular Sequence Data; Paclitaxel; Pancreatic Neoplasms; Peptide Hydrolases; Peptides; Rats; Taxoids; Tubulin; Tumor Cells, Cultured | 2000 |
Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Paclitaxel; Remission Induction; Salvage Therapy; Taxoids | 2000 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
[A patient with recurrent breast cancer whose liver metastasis regressed following combined use of weekly docetaxel and MPA.5'-DFUR].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Paclitaxel; Taxoids | 2001 |
[A case of locally advanced breast cancer successfully treated with wide resection and reconstruction of chest wall with A-O metallic plates].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Paclitaxel; Plastic Surgery Procedures; Quality of Life; Surgical Mesh; Survivors; Taxoids | 2001 |
[Local therapy for stage IV advanced breast cancer with brain metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Radiosurgery; Tamoxifen; Taxoids | 2001 |
[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Ethanol; Fadrozole; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Tegafur; Uracil | 2001 |
Challenges in oncology. Case 2. Radiation recall associated with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Paclitaxel; Radiation Injuries; Radiotherapy; Skin; Taxoids | 2002 |
Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids; Treatment Outcome | 2000 |
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Drug Monitoring; Epirubicin; Female; Fluorouracil; Humans; Mammography; Mastectomy; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Paclitaxel; Physical Examination; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |